Finance
HIMSS21
Reenita Das, partner and SVP for healthcare and life sciences at Frost and Sullivan, said that femtech companies only accounted for 1.8% of total digital health investments in 2020.
Also: Entos works to improve drug development after closing its Series A round and Castor plans to build out its decentralized clinical trial platform with a $45 million investment.
Once combined, the company will operate as HeartFlow Group and trade on the NYSE under symbol HFLO.
The proceeds will be used to fund the clinical development of MyopiaX, the company's lead product in childhood myopia.
The Israeli company now has a total of $9 million in venture funding.
This brings the company's total raise to $140 million.
The company is planning on using the new funds to expand its library and build more capabilities.
The Boston and Tel Aviv-based company includes a predictive analytics tool which helps intervene in a person's aging trajectory.
Together the businesses have 900,000 subscribers.
The app aims to give users customised insights to help gain a holistic understanding of what impacts their overall health, mood and fitness.